An exceptional case of myelodysplastic syndrome with myelofibrosis following combination chemotherapy for squamous cell lung cancer  

作　　者：Yi-Hao Wang Rong Fu Zong-Hong Shao 

机构地区：[1]Department of Hematology, Tianjin Medical University General Hospital

出　　处：《Cancer Biology & Medicine》2013年第2期117-120,共4页癌症生物学与医学（英文版）

基　　金：supported by the Tianjin Bureau of Public Health (Grant No. 2010KZ105);Tianjin Medical University(Grant No. 2010ky20);the National Natural Science Foundation of China (Grant No. 30971286, 30971285)

摘　　要：A 60-year-old woman with squamous cell carcinoma in the right lung was successfully treated with four cycles of combination chemotherapy after surgery, and complete remission was achieved. However, the patient developed myelodysplastic syndrome (MDS) RAEB-2 with myelofibrosis after remission, possibly because of chemotherapy or DNA methylation. The patient responded well to dacitabine (Dacogen), suggesting that DNA hypomethylation agents can be a promising therapy to retard the progression of a second tumor or carcinoma.A 60-year-old woman with squamous cell carcinoma in the right lung was successfully treated with four cycles of combination chemotherapy after surgery, and complete remission was achieved. However, the patient developed myelodysplastic syndrome （MDS） RAEB-2 with myelofibrosis after remission, possibly because of chemotherapy or DNA methylation. The patient responded well to dacitabine （Dacogen）, suggesting that DNA hypomethylation agents can be a promising therapy to retard the progression of a second tumor or carcinoma.

关 键 词：DNA methylation myelodysplastic syndrome MYELOFIBROSIS squamous cell lung cancer 

分 类 号：R551.3[医药卫生—血液循环系统疾病] R734.2[医药卫生—内科学]